Free Trial
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

IDEXX Laboratories logo
$543.53 +2.89 (+0.53%)
As of 10:21 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About IDEXX Laboratories Stock (NASDAQ:IDXX)

Key Stats

Today's Range
$538.19
$541.90
50-Day Range
$471.38
$546.31
52-Week Range
$356.14
$549.52
Volume
20,897 shs
Average Volume
727,697 shs
Market Capitalization
$43.71 billion
P/E Ratio
50.29
Dividend Yield
N/A
Price Target
$558.11
Consensus Rating
Moderate Buy

Company Overview

IDEXX Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

IDXX MarketRank™: 

IDEXX Laboratories scored higher than 79% of companies evaluated by MarketBeat, and ranked 215th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IDEXX Laboratories has only been the subject of 4 research reports in the past 90 days.

  • Read more about IDEXX Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEXX Laboratories are expected to grow by 13.83% in the coming year, from $11.93 to $13.58 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEXX Laboratories is 50.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.72.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEXX Laboratories is 50.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.44.

  • Price to Earnings Growth Ratio

    IDEXX Laboratories has a PEG Ratio of 3.93. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    IDEXX Laboratories has a P/B Ratio of 27.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about IDEXX Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    3.19% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently decreased by 1.17%, indicating that investor sentiment is improving.
  • Dividend Yield

    IDEXX Laboratories does not currently pay a dividend.

  • Dividend Growth

    IDEXX Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.19% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently decreased by 1.17%, indicating that investor sentiment is improving.
  • News Sentiment

    IDEXX Laboratories has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 24 news articles for IDEXX Laboratories this week, compared to 18 articles on an average week.
  • Search Interest

    5 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,182,920.00 in company stock.

  • Percentage Held by Insiders

    Only 0.98% of the stock of IDEXX Laboratories is held by insiders.

  • Percentage Held by Institutions

    87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEXX Laboratories' insider trading history.
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
IDXX - IDEXX Laboratories Inc Sustainability - Morningstar
IDXX IDEXX Laboratories, Inc. - Seeking Alpha
See More Headlines

IDXX Stock Analysis - Frequently Asked Questions

IDEXX Laboratories' stock was trading at $413.44 at the beginning of the year. Since then, IDXX stock has increased by 31.5% and is now trading at $543.5290.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings data on Thursday, May, 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories's quarterly revenue was up 3.6% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional investors of IDEXX Laboratories include Seilern Investment Management Ltd (0.26%), Swedbank AB (0.04%), Bourne Lent Asset Management Inc. (0.04%) and Woodstock Corp (0.03%). Insiders that own company stock include Jonathan W Ayers, Jonathan Jay Mazelsky, Brian P Mckeon, James F Polewaczyk, George Fennell, Kathy V Turner, Michael Lane, Daniel M Junius, Sophie V Vandebroek, M Anne Szostak and Bruce L Claflin.
View institutional ownership trends
.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include Tesla (TSLA), Broadcom (AVGO), Applied Materials (AMAT), HubSpot (HUBS), ASML (ASML), CrowdStrike (CRWD) and Cadence Design Systems (CDNS).

Company Calendar

Last Earnings
5/01/2025
Today
7/10/2025
Next Earnings (Confirmed)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
CIK
874716
Employees
11,000
Year Founded
1983

Price Target and Rating

High Price Target
$625.00
Low Price Target
$510.00
Potential Upside/Downside
+3.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
49.97
Forward P/E Ratio
45.32
P/E Growth
3.93
Net Income
$887.87 million
Pretax Margin
28.60%

Debt

Sales & Book Value

Annual Sales
$3.90 billion
Cash Flow
$12.47 per share
Price / Cash Flow
43.35
Book Value
$19.48 per share
Price / Book
27.75

Miscellaneous

Free Float
79,634,000
Market Cap
$43.48 billion
Optionable
Optionable
Beta
1.54

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:IDXX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners